Daniel B. Soland

Daniel B. Soland (senior executive) discloses dealings in 3 companies, chiefly Acadia Pharmaceuticals Inc, DBV Technologies S.A. and Idera Pharmaceuticals, Inc. The record holds 5 filings, for trades running from 18 June 2021 to 29 May 2025.

Purchases make up the whole of the open-market record (2 purchases, €72k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 option exercises.

Most recently, on 2 June 2025, the filings show an option exercise in Acadia Pharmaceuticals Inc. The clock since the last published purchase (3 August 2023) now reads 1,172 days. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.